title: "MULTINATIONAL, PHASE III, RANDOMIZED STUDY TO EVALUATE TREATMENT CUSTOMIZED ACCORDING TO RAP 80 AND BRCA1 mRNA ASSESSMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (modification of the BREC study) "

acronym: BREC

lead_sponsor: ADDS (Advanced Drug Development Services)


title: A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY

source: euctr

lead_sponsor: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

study_type: Interventional

status: Ongoing

lead_sponsor_type: industriel

status_simplified: Ongoing


title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence

lead_sponsor: Allergan Ltd


title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma

lead_sponsor: CHU de Dijon

status: Completed

lead_sponsor_type: academique

status_simplified: Completed


title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis.

acronym: BATT (Biclutamide anatrozole treatment for testotoxicosis)

lead_sponsor: AstraZeneca AB


title: A Phase I Study of Ridaforolimus in Pediatric Patients with Advanced Solid Tumors

acronym: Oral MK8669 in Children/Adolescents with Solid Tumors (8-17 years)

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: Evaluation de l’efficacité de l’association ibuprofène et codéine versus l’ibuprofène seul dans le traitement de la poussée douloureuse de la gonarthrose. Etude en double aveugle, randomisée contrôlée de 2 groupes parallèles de patients traités pendant 7 jours.

acronym: EVACOD

lead_sponsor: Laboratoires ELERTE


title: An Open Label Multicenter Extension Study to Evaluate the Long-Term Efficacy and Safety of SBC 102 in Children with Lysosomal Acid Lipase Deficiency Who Previously Received Treatment with SBC-102

acronym: SBC-102 in Children with Growth Failure Due to Lysosomal Acid Lipase Deficiency

lead_sponsor: Synageva Biopharma Corp.

status_simplified: Unknown


title: A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or 5x10E8 TU doses to placebo in HIV-1 clade B infected patients under highly active antiretroviral therapy

lead_sponsor: THERAVECTYS


title: IMPACTS Trial:  Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study:  Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients with Sickle Cell Disease and Vaso-occlusive Crisis)

lead_sponsor: Anthera Pharmaceuticals Incorporated


title: A randomized, double-blind, placebo-controlled, 4 period incomplete block cross-over, multi-center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 in patients with stable Chronic Obstructive Pulmonary Disease (COPD), compared to seven days treatment with tiotropium (18µg once daily, open label) as an active control.

lead_sponsor: Novartis Pharma Services AG


title: Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)

acronym: NIVO-ALCL

lead_sponsor: Gustave Roussy


title:
An open-label, multi-center rollover protocol for patients
 who have participated in a Novartis-sponsored ribociclib
 (LEE011) study and are continuing to benefit from
 ribociclib as single agent or in combination with other
 investigational treatments

 Protocole multicentrique en ouvert évaluant la poursuite du traitement par ribociclib (LEE011) chez des patients ayant terminé leur participation à une étude promue par Novartis et qui continuent de bénéficier du ribociclib seul ou associé à d’autres traitements expérimentaux


title: A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple  Myeloma

lead_sponsor: Amgen Inc


title: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

acronym: Parsaclisib Rollover study

lead_sponsor: Incyte Corporation


title:
First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients

 Étude de première administration chez l’homme visant à évaluer la sécurité d’emploi, la tolérance, la pharmacocinétique, la pharmacodynamique et l’efficacité préliminaire du PPSGG (PN-1007) chez des patients atteints de neuropathie anti-MAG.

lead_sponsor: Polyneuron Pharmaceuticals AG


title: A phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be due to Gram-Positive Organisms

lead_sponsor: Durata Therapeutic International B.V.


title: A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to <18 Years of Age with Moderate to Severe Chronic Plaque Psoriasis

lead_sponsor: Sun Pharma Advanced Research Company Ltd.


title:
A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory BAP1 deficientMalignant Mesothelioma

 Étude multicentrique de phase II de l’inhibiteur de l'EZH2 Tazemetostat chez des patients adultes atteints d'un mésothéliome malin en rechute ou réfractaire avec perte de fonction BAP1

lead_sponsor: Epizyme, Inc.


title:
Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both or neither

 Essai clinique randomisé multicentrique du traitement endovasculaire de l’accident vasculaire cérébrale ischémique aigu. Effet du traitement médicamenteux péri-interventionnel : acide acétylsalicylique, héparine non fractionnée, les deux ou aucun

acronym:
MR CLEAN - MED

 MR CLEAN - MED

lead_sponsor: Erasmus MC University Medical Center

status: Prematurely Ended


title: Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma

lead_sponsor: Centre Oscar Lambret


title: A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy

lead_sponsor: Cliniques Universitaires St Luc


title: A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

acronym: PYTHON

lead_sponsor: CYCLOPHARMA


title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs

acronym: HDL functionality

lead_sponsor: F. HOFFMANN-LA ROCHE LTD


title: Sevrage de la ventilation mécanique guidé par le peptide natriurétique de type B.

acronym: BMW

lead_sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)


title: ETUDE INTERNATIONALE DE PHASE II EVALUANT UNE ASSOCIATION CHOP-RITUXIMAB AVEC CONSOLIDATION PRECOCE PAR IBRITUMOMAB-TIUXETAN-Y90 CHEZ DES PATIENTS AGES DE 65 ANS A 80 ANS ATTEINTS D'UN LYMPHOME MALIN A GRANDES CELLULES CD20+ NON PRETRAITES

acronym: CHORIZO

lead_sponsor: CENTRE ANTOINE LACASSAGNE


title: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment

lead_sponsor: Allergan


title: OPTIMAL CONTROL OF LIVER METASTASES WITH INTRAVENOUS CETUXIMAB AND HEPATIC ARTERY INFUSION OF THREE-DRUG CHEMOTHERAPY IN PATIENTS WITH LIVER-ONLY METASTASES FROM COLORECTAL CANCER. A PHASE II TRIAL

lead_sponsor: ARTBC


title: Efficacy and Safety Assessment of Azyter® (T1225) in Peri-Operative Antibio-Prophylaxis (ocular surface decontamination) for Cataract Surgery

lead_sponsor: Laboratoires Théa


title: Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma


title: Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma.


title: Etude de phase III randomisée, ouverte, multicentrique comparant chez des sujets âgés de plus de 70 ans atteints de cancer bronchique non à petites cellules de stade IV ou IIIb (T4 plèvre ou péricarde) une stratégie « classique » d’attribution d’un traitement par bithérapie à base de carboplatine ou une monothérapie par Docetaxel seul basée sur le PS et l’âge à une stratégie « optimisée » utilisant les mêmes drogues attribuées selon une échelle gériatrique simplifiée de dépistage plus ou moins complétée d’une évaluation gériatrique approfondie

acronym: esogia

lead_sponsor: CHU de Rennes


title: A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients with Stages 3 to 5 Chronic Kidney Disease Undergoing MRI with the Injection of ProHance

acronym: Evaluation of the Incidence of NSF Following ProHance Injection

lead_sponsor: Bracco Imaging S.p.A.


title:
A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma.

 Etude de phase Ib/II de l’Obinutuzumab (GA101) combiné au lenalidomide pour le traitement du lymphome folliculaire et du lymphome agressif à cellules B (DLBCL et MCL) réfractaire ou en rechute.

acronym: GALEN

lead_sponsor: GELARC


title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002

lead_sponsor: Edimer Pharmaceuticals, Inc.


title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)

lead_sponsor: INSERM


title:
D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study

 INTERET DE LA CHIMIOHYPERTHERMIE INTRAPERITONEALE (CHIP) ADJUVANTE A L’OXALIPLATINE DANS LE TRAITEMENT CURATIF DES CANCERS GASTRIQUES AVANCES. ETUDE NATIONALE, RANDOMISEE ET MULTICENTRIQUE DE PHASE III.

acronym:
GASTRICHIP

 GASTRICHIP

lead_sponsor: Hospices Civils de Lyon


title: FIVHeMA: Intraventricular fibrinolysis versus external ventricular drainage alone in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.

acronym: FIVHEMA

lead_sponsor: CHU CAEN


title: SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy

lead_sponsor: Asahi Kasei Pharma America Corporation


title: Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)

lead_sponsor: NeuroVia, Inc.


title: Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA

lead_sponsor: Abeona Therapeutics Inc


title: A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled with topical therapies - PRELUDE

acronym: PRELUDE

lead_sponsor: Novartis Pharma AG


title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)

lead_sponsor: Innovent Biologics (Suzhou) Co., Ltd.


title: A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis

lead_sponsor: Novartis Pharma Services AG


title:
A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma
 Revised Protocol Number 01, incorporating Amendment 02 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06

lead_sponsor: Bristol-Myers Squibb International Corporation


title: An Open-Label Extension Study Evaluating the Long-Term Safety of ICA 17043 with or without Hydroxyurea Therapy in Subjects with Sickle Cell Disease

lead_sponsor: Icagen Inc.


title: A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of multiple oral doses of AFQ056


title: Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose  péritonéale d'origine colorectale associée à une chimiothérapie systémique.

acronym: CHIP

lead_sponsor: FNCLCC


title:
A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients
 Revised Protocol Number 02, incorporating amendments 03 and 04


title: VALIDATION OF DYSKINESIA RATING SCALES

lead_sponsor: Michael J. Fox Foundation for Parkinson’s Research


title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF  I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)

lead_sponsor: LFB BIOTECHNOLOGIES


title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children

lead_sponsor: Advicenne


title:
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia

 Une étude ouverte multicentrique avec titrage de la posologie du chlorhydrate de nevanimibe dans le traitement de l’hyperplasie congénitale des surrénales classique

lead_sponsor: Millendo Therapeutics, Inc.


title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)

lead_sponsor: Fulcrum Therapeutics, Inc.


title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)

lead_sponsor: HANLIM PHARM CO., LTD


title: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer

lead_sponsor: ARIAD Pharmaceuticals, Inc.


title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previously untreated adults with B and C Binet stage B-chronic lymphoid leukemia (B-CLL).

acronym: CLL 2007 FMP

lead_sponsor: GOELAMS


title: A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing  SCH 420814 5 mg BID

lead_sponsor: Schering Plough Research Institute


title: Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5083945, a Glycoengineered Antibody against EGFR, in patients with metastatic and/or locally advanced malignant EGFR+ Solid Tumors

lead_sponsor: F. Hoffmann-La Roche Ltd


title: A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB)

lead_sponsor: Genentech, Inc.


title:
SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation.
 An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients with Atrial Fibrillation undergoing Electric Cardioversion Following Transesophageal Echocardiography.

acronym: SAFE-AF

lead_sponsor: GlaxoSmithKline R & D


title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Two-arm Safety and Efficacy Study of SYN118 as Adjunctive Therapy in Subjects with Parkinson‟s Disease

lead_sponsor: Synosia Therapeutics AG


title: A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia

lead_sponsor: Clavis Pharma ASA


title:
A phase I/II multicenter, open-label study of CLR457 administered orally
 in adult patients with advanced solid malignancies

lead_sponsor: Novartis Pharma Services AG


title: A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias

lead_sponsor: Osmotica Pharmaceutical Corp.


title:
IFM 2014-02 study: A randomized phase III study of Bortezomib-Melphalan 200 conditioning regimen versus Melphalan 200 for frontline transplant eligible patients with multiple myeloma

 Etude IFM 2014-02:
 Intérêt d’un conditionnement par bortezomib-melphalan 200 vs melphalan 200 suivi d’une autogreffe de cellules souches chez les patients de moins de 66 ans atteints de myélome multiple en première ligne: une étude randomisée de phase III de l’IFM

acronym: Etude IFM 2014-02

lead_sponsor: CHU Toulouse


title:
A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism
 Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

acronym: PARTUM

lead_sponsor: CHU SAINT-ETIENNE


title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in Patients with Previously Treated, incurable Ewing Sarcoma

lead_sponsor: Sarcoma Alliance for Research Through Collaboration (SARC)


title: A randomized, open label multicenter trial to investigate the efficacy of a treat-to-target treatment strategy with secukinumab (AIN457) as a first-line biologic compared to a standard-of-care treatment over 36 weeks in patients with active axial spondyloarthritis (axSpA) - AScalate

acronym: AScalate

lead_sponsor: Novartis Pharma GmbH


title: A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer

acronym: TENACITY

lead_sponsor: Ayala Pharmaceuticals, Inc.


title:
OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

 Étude de phase 2, multicentrique, en ouvert visant à évaluer l’IFX-1, un anticorps anti-C5a, administré en monothérapie ou en association avec le pembrolizumab chez des patients présentant un carcinome épidermoïde cutané (CEC) localement avancé ou métastatique résistant/réfractaire aux anticorps anti-PD-1 ou anti-PD-L1

lead_sponsor: InflaRx GmbH


title:
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone

 DENOEUROSARC-007 - Etude de phase 2 multicentrique, en ouvert du denosumab chez des patients présentant des tumeurs osseuses riches en cellules géantes

acronym:
DENOEUROSARC-007

 DENOEUROSARC-007

lead_sponsor: Leiden University Medical Center


title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therapy) administered in combination with anti-VEGF therapy

lead_sponsor: OPHTHOTECH CORPORATION


title:
Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemia

 Évaluation de la l'efficacité, du délai d'action, et de la tolérance de Tot'héma® chez l'adulte présentant une anémie modérée ferriprive

acronym: FAST

lead_sponsor: Laboratoire Innotech Internationnal


title: A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson’s disease

lead_sponsor: Integrative Research Laboratories Sweden AB (IRLAB)


title:
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

 Étude de phase 2 à double cohorte, en ouvert portant sur le brentuximab védotine et le CHP (A+CHP) dans le traitement de première ligne de patients atteints de lymphome à cellules T périphérique (LCTP) avec moins de 10 % d’expression de CD30

lead_sponsor: Seattle Genetics, Inc.


title:
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

 Étude de phase III, randomisée, en ouvert, contrôlée, multicentrique, évaluant l’efficacité et la tolérance du Savolitinib versus Sunitinib chez des patients atteints d’un carcinome papillaire rénal non opérable localement avancé ou métastatique avec mutation MET

lead_sponsor: AstraZeneca


title:
Phase I/II feasibility study of Brentuximab Vedotin in refractory / relapsed Hodgkin lymphoma patients who are treated by chemotherapy (ICE) in second line and eligible for autologous transplantation

 Etude de faisabilité de phase I/II du Brentuximab vedotin chez des patients atteints d'un Lymphome de Hodgkin en rechute ou réfractaire, traités par chimiothérapie (ICE) en seconde ligne et éligibles à l'autogreffe.

acronym: BV-ICE

lead_sponsor: LYSARC


title:
A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions

 Etude de phase II évaluant le nivolumab seul ou en association à la vinblastine chez des patients atteints d’un lymphome de Hodgkin classique, âgés de 61 ans et plus et présentant des co-morbidités


title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA

acronym: VALYM


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis

acronym: Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS

lead_sponsor: Biogen Idec Research Limited


title: A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders.

lead_sponsor: Neurochlore


title:
A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome

 Étude de phase II multicentrique non-randomisée évaluant le traitement par un inhibiteur d’IDH1 (AG-120) chez des patients présentant un syndrome myélodysplasique avec mutation IDH1

lead_sponsor: Groupe Francophone des Myelodysplasies


title: Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have received radical surgery. A European Association of Urology Research Foundation Phase II Clinical Trial

acronym: Adjuvant Pemigatinib in surgically treated high-risk UC

lead_sponsor: EAU Research Foundation


title:
Comparison of the analgesic effect of a new paracetamol formulation (paracetamol UNIFLASH) for buccal use and two different doses of an oral paracetamol form controlled versus placebo in patients suffering from moderate pain due to a tooth extraction.

 Comparaison de l’effet analgésique d’une nouvelle formulation de paracétamol (paracétamol UNIFLASH) à usage buccal et de deux doses différentes d’une forme orale de paracétamol, contrôlée versus placebo, chez des patients souffrant de douleurs modérées dues à une extraction dentaire

acronym: PARAMOUTH

lead_sponsor: UNITHER Pharmaceuticals


title: A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

lead_sponsor: Incyte Corporation


title: Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

acronym: Mogamulizumab Q4week dosing in Participants with R/R CTCL

lead_sponsor: Kyowa Kirin Inc.


title: Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patients.

lead_sponsor: DOMPE FARMACEUTICI S.P.A.


title: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome

lead_sponsor: Emalex Biosciences, Inc.


title: Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy

lead_sponsor: AXCAN PHARMA SAS


title: A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

lead_sponsor: SynCore Biotechnology Co., Ltd.


title:
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis treated by R-CHOP

 Etude de phase Ib-II du tazemetostat (EPZ-6438) chez des patients
 atteints de lymphome diffus à grandes cellules B (DLBCL) de
 risque élevé traités par R-CHOP


title: A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II.

acronym: ACCELA

lead_sponsor: sanofi-aventis recherche & développement


title: A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chronic hepatitis B.

acronym: NEPTUNE

lead_sponsor: F.Hoffmann-La Roche Ltd


title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.

lead_sponsor: Galderma Research and Development SNC


title: A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis.

acronym: Transition to RNF

lead_sponsor: Merck Serono International SA


title: Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Twelve-week treatment plus double-blind extension for 12 weeks.

lead_sponsor: Institut de Recherches Internationales Servier


title: A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator-Associated Pneumonia

lead_sponsor: Janssen Cilag International NV


title: A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma

acronym: IGF-1R protocol

lead_sponsor: Cliniques Universitaires Saint Luc-Centre du Cancer


title: A randomized, open-label, controlled, multi-center Phase II study to evaluate the efficacy and safety of adecatumumab alone or sequentially to FOLFOX relative to FOLFOX after R0 resection of colorectal liver metastases

lead_sponsor: Micromet AG


title: An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of  a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older

lead_sponsor: Sanofi Pasteur MSD S.N.C.


title: A phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Infants Aged 1 to 11 months, Inclusive

lead_sponsor: AstraZeneca AB


title: Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.

lead_sponsor: Orfagen


title: A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older


title: Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44

acronym: Principle -TIMI 44

lead_sponsor: Eli Lilly and Company


title: An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression.

lead_sponsor: Boehringer Ingelheim France


title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, 100 and 200 mg) vs Placebo in Patients with Overactive Bladder.

lead_sponsor: Helsinn Healthcare SA


title: A MULTICENTER, RANDOMIZED, INTRA-INDIVIDUAL, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD2027 OINTMENT 9µG/G APPLIED TWICE DAILY OVER 4 WEEKS IN THE TREATMENT OF TARGET LESIONS IN ADULTS SUBJECTS WITH ATOPIC DERMATITIS.

lead_sponsor: Galderma R&D SNC


title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regimen

acronym: DORAL

lead_sponsor: Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida  (CREPATS)


title: Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 15-Aug-06)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant

lead_sponsor: AlloVir, Inc.


title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma

lead_sponsor: Nerviano Medical Sciences S.r.l.


title:
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)

 Étude de phase 3, prospective, randomisée, en double aveugle, contrôlée par comparateur actif, multicentrique, à deux bras, visant à évaluer l’efficacité et la sécurité d’emploi du KSI-301 par voie intravitréenne comparativement à l’aflibercept par voie intravitréenne chez des participants présentant une déficience visuelle secondaire à un œdème maculaire diabétique (OMD) n’ayant jamais reçu de traitement

acronym: GLIMMER

lead_sponsor: Kodiak Sciences Inc.


title: A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

lead_sponsor: Pharma Mar, S.A.


title:
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy (DUART)

 Étude de phase 2 internationale, ouverte, multicentrique, évaluant le durvalumab après radiothérapie chez des patients atteints de cancer du poumon non à petites cellules non résécable de stade III qui ne sont pas éligibles à la chimiothérapie (étude DUART)

acronym: DUART


title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)

lead_sponsor: Cellectar Biosciences, Inc.


title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

lead_sponsor: Dova Pharmaceuticals, Inc.


title: An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15μg) versus an Inactivated adjuvanted Influenza Vaccine administered by Intramuscular Route (Addigrip® 15µg) in subjects 65 years of age or older

lead_sponsor: Sanofi Pasteur MSD


title: A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders.


title:
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer’s Disease or With Mild Alzheimer’s Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects with Asymptomatic Amyloid-Related Imaging Abnormalities

 Étude de phase 2 contrôlée, multicentrique, randomisée, en groupes parallèles et en double aveugle portant sur de l’aducanumab (BIIB037) chez des patients atteints de troubles cognitifs légers dus à la maladie d’Alzheimer ou de la maladie d’Alzheimer au stade léger, dont le but est d’évaluer la sécurité d’emploi lorsque l’on poursuit l’administration chez des patients présentant des anomalies d’imagerie  liées à l’amyloïde (ARIA) asymptomatiques

lead_sponsor: Biogen Idec Research Limited


title:
A Phase 3b Open-label Study of the Anti-FGF23 Antibody,
 Burosumab (KRN23) in Adult Patients with X-linked
 Hypophosphatemia (XLH)

 Étude de phase IIIb en ouvert sur l'anticorps anti-FGF23, le burosumab
 (KRN23), chez des adultes atteints d'hypophosphatémie liée à l'X (ou XLH
 pour X-linked Hypophosphatemia)

lead_sponsor: Kyowa Kirin Pharmaceutical Development Ltd


title: Long-term, open-label, multicenter extension study of bosentan in patients with pulmonary hypertension associated with sickle cell disease completing a double-blind ASSET study (AC-052-368 or AC-052-369)

lead_sponsor: Actelion Pharmaceuticals Ltd.


title: Randomised, double-blind, placebo-controlled, Phase II study to assess the safety and efficacy of different doses of intravenous APD405 (buspirone for IV injection) for the prevention of post-operative nausea and vomiting

lead_sponsor: Acacia Pharma Ltd.


title: A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with severe COVID-19

acronym: ESsCOVID

lead_sponsor: Biotest AG


title: A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODOMAL TO MILD) ALZHEIMER'S DISEASE

lead_sponsor: F. Hoffmann-La Roche Ltd


title: Standardized sTudy with Almotriptan in eaRly Treatment of migraine, START. An international, open-label, single arm, effectiveness and safety study of Almotriptan in primary care seeting.

acronym: START

lead_sponsor: Laboratorios Almirall SA


title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone.

lead_sponsor: F.Hoffmann-La Roche Ltd


title:
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study

 Étude d'extension du Tazemetostat (TRuST) : une étude d'extension en ouvert

lead_sponsor: Epizyme, Inc.


title: A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease

lead_sponsor: Wave Life Sciences UK Limited


title: A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations.

acronym: MK-1439A in treatment-naïve HIV-1 infected subjects with NNRTI transmitted resistance.

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


title: A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment

lead_sponsor: Gilead Sciences, Inc.


title:
A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

 Étude multinationale dans le but de recueillir des échantillons de sang pour l’exploration de paramètres génétiques et de biomarqueurs potentiels liés à une augmentation du risque de lésion hépatique chez les patients adultes ayant précédemment participé aux essais cliniques du tolvaptan dans le traitement de la polykystose rénale autosomique dominante (PKRAD)

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.


title: A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease

acronym: Safety&Efficacy of Comb. Respimat  COPD

lead_sponsor: Boehringer Ingelheim France


title: A Randomised, Double-Blind, Single dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients

acronym: LIP

lead_sponsor: Bioalliance Pharma


title: A randomized, double-blind, placebo-controlled, cross-over trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by functional magnetic resonance imaging (FMRI) of the brain

lead_sponsor: Aarhus University


title: A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular toxicity in cancer patients treated with SYD985.

lead_sponsor: Byondis B.V.


title: Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain

acronym: HMEN

lead_sponsor: Eli Lilly and Company Ltd.


title: Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine (T4) soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients.

lead_sponsor: IBSA, Institut Biochimique SA


title: An Eight-Week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients with Major Depressive Disorder

acronym: INDIGO

lead_sponsor: sanofi-aventis recherche & développement


title:
An Open-Label Extension Study of XEN496 in Pediatric Subjects with KCNQ2 Developmental and Epileptic Encephalopathy

 Étude d’extension en ouvert évaluant le XEN496 chez des patients pédiatriques présentant une encéphalopathie épileptique et développementale associée à KCNQ2

acronym: EPIK OLE

lead_sponsor: Xenon Pharmaceuticals Inc.


title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises

lead_sponsor: Global Blood Therapeutics, Inc.


title: A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy

lead_sponsor: Novartis Pharma Services AG


title:
A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still’s disease (including systemic juvenile idiopathic arthritis and Adult onset Still’s disease) or with MAS in Systemic lupus erythematous

 Étude multicentrique, sur deux cohortes, menée en ouvert, à bras unique, visant à évaluer l’efficacité, la sécurité d’emploi et la tolérance, ainsi que la pharmacocinétique et la pharmacodynamique de l’émapalumab chez des enfants et des adultes atteints du syndrome d’activation macrophagique (SAM) dans la maladie de Still (incluant la forme systémique d’arthrite juvénile idiopathique et la maladie de Still de l’adulte) ou atteints du SAM dans le lupus érythémateux systémique

lead_sponsor: Swedish Orphan Biovitrum AG (Sobi AG)


title: A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy

lead_sponsor: TopoTarget A/S


title:
A Phase II, randomized, double-blind, parallel group dose finding study of single oral doses of moxidectin in adults with scabies

 Étude de phase II, randomisée, en double aveugle, en groupes parallèles, destinée à l'établissement de la posologie de la moxidectine en prise unique par voie orale chez des adultes atteints de la gale

lead_sponsor: Medicines Development Limited (trading as Medicines Development for Global Health)


title: A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).

lead_sponsor: ONO Pharmaceutical Co., Ltd.


title:
A placebo-controlled, patient and investigator blinded, randomized parallel
 cohort study to assess pharmacodynamics, pharmacokinetics, safety,
 tolerability and preliminary clinical efficacy of VAY736 and CFZ533 in
 patients with systemic lupus erythematosus (SLE)

 Étude randomisée, en double aveugle contre placebo, en groupes parallèles visant à évaluer la pharmacodynamie, la pharmacocinétique, la sécurité, la tolérabilité et l'efficacité clinique préliminaire de VAY736 et CFZ533 chez des patients atteints de lupus érythémateux disséminé

lead_sponsor: Novartis Pharma AG


title:
An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES

 Etude de phase II multicentrique, en ouverte, afin d’évaluer l'efficacité et la tolérance des IdeS dans la glomérulonéphrite anti-MBG (syndrome de Goodpasture) avec atteinte rénale sévère. GOOD-IdeS.

acronym: GOOD-IDES

lead_sponsor: Linköping University


title:
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

 Essai clinique en ouvert, à bras unique de phase II des lymphocytes T ADP-A2M4 SPEARTM chez des patients atteints de sarcome synovial avancé ou de liposarcome myxoïde/à cellules rondes (LSMCR)

acronym: SPEARHEAD 1 STUDY

lead_sponsor: Adaptimmune LLC


title: A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate Response to Methotrexate. Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 19-Dec-2007); Revised Protocol 01, incorporating administrative letter 01 and amendment 03 (version 1.0, dated 12-Mar-2008)

lead_sponsor: Bristol Myers Squibb International Corporation


title: A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus

lead_sponsor: Merz Pharmaceuticals GmbH


title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multi-centre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modulator ADX10059 in patients with Gastroesophageal Reflux Disease (GERD) who are partial responders to proton pump inhibitor (PPI) treatment.

lead_sponsor: Addex Pharma SA


title: In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX)

lead_sponsor: Wyeth Pharmaceuticals


title:
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination with Metformin
 + Pharmacogenetics Blood Sample Protocol Amendment 1 (v1.0, Date 13-Aug-2008)

lead_sponsor: Bristol-Myers Squibb International Corporation


title: A Phase 2, Randomized, Open-Label Study to Evaluate ECG 	Results and Pharmacokinetic Parameters for Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia.

lead_sponsor: Biogen Idec Ltd


title: EFFICACY STUDY OF THE ANTIHISTAMINE V0114 CP 2.5MG TABLET IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS.  A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer.


title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibrate 160mg/Pravastatin 40mg combination versus Simvastatin 20mg in patients without Cardiovascular disease (CVD) (group 1) and of Fenofibrate 160mg/Pravastatin 40mg combination+Ezetimibe 10mg versus Simvastatin 20mg+Ezetimibe 10mg in patients with CVD (group 2), followed by a 12-week safety phase of  Fenofibrate 160mg/Pravastatin 40mg combination in group 1 and of Fenofibrate 160mg/Pravastatin 40 mg combination+Ezetimibe 10mg in group 2.

acronym: PREFED "PRavastatin, Ezetimibe and FEnofibrate in Diabetic patients"

lead_sponsor: Laboratoires SMB S.A.


title:
Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection.
 Revised Protocol 01, incorporating Amendment 02 (Version 1.0 Date 20-Nov-2006).


title: A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT-WITHDRAWAL STUDY OF THE EFFICACY AND SAFETY OF PANTOPRAZOLE SODIUM ENTERIC-COATED GRANULES IN INFANTS (1 THROUGH 11 MONTHS) WITH SYMPTOMATIC GERD.

lead_sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development


title: Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers

lead_sponsor: Pharma Mar, S.A.


title: A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury

lead_sponsor: Cephalon Inc.


title: Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia

acronym: PERTAIN

lead_sponsor: Janssen-Cilag International NV, Turnhoutsweg 30, 2340 BEERSE, Belgium


title: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis

acronym: Not applicable

lead_sponsor: FoldRx Pharmaceuticals, Inc.


title: Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anemia

lead_sponsor: Schering-Plough Research Institution, A Division of Schering Corporation


title: An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study

acronym: Open label extension study to verify long term safety of OxabactTM , the Phoenix II study

lead_sponsor: OxThera, Inc.


title: Non inferiority study of a malathion 0.5% lotion versus reference therapy in the treatment of head lice: multicentre, randomised, investigator masked, parallel group.

lead_sponsor: Pierre Fabre Dermo-Cosmétique


title: A Phase III open-label titration trial to evaluate the effectiveness and safety of different doses of a dermal application of Testosterone MD-Lotion® (cutaneous solution) in hypogonadal men

lead_sponsor: Acrux Pharma Pty Ltd


title: A randomized, double-blind, placebo controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in doses 60 mg, 120 mg, 180 mg and 240 mg bid as add-on treatment to a PPI in patients with GERD that are partial responders to PPI treatment

lead_sponsor: AstraZeneca AB


title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation.

lead_sponsor: Theratechnologies Inc.


title: A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Refractory Heel Enthesitis in Spondylarthropathy

lead_sponsor: Wyeth Pharmaceuticals France


title: A double-blind, randomised study comparing the safety and tolerance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition

lead_sponsor: Fresenius Kabi Deutschland GmbH


title: A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)

acronym: CYSIF

lead_sponsor: GETAID


title: A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects

lead_sponsor: Astellas Pharma US, Inc.


title: An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy


title: A Phase III, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0826/Ertapenem and Meropenem in Patients with Complicated Urinary Tract Infections

lead_sponsor: Merck & Co., Inc.


title: A Phase 3, Open-label, Multicenter, Prospective, Randomized Study of the Efficacy and Safety of Conversion from Prograf® Capsules Twice Daily to LCP-Tacro™ Tablets Once Daily for the Prevention of Acute Allograft Rejection in Stable Kidney Transplant Patients

lead_sponsor: LifeCycle Pharma A/S


title: A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with Chronic Hepatitis C

lead_sponsor: Gilead Sciences Incorporated


title: Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab

acronym: EUSpA

lead_sponsor: Schering-Plough France


title: Plasma Pharmacokinetics study of CD5024 1% cream in subjects with papulopustular rosacea

lead_sponsor: GALDERMA R&D SNC


title: RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB

acronym: LAP 07

lead_sponsor: GERCOR


title: Belatacept Conversion Trial in Renal Transplantation

lead_sponsor: Bristol-Myers Squibb International Corporation


title: ASSESSMENT OF GLOBAL AND REGIONAL LEFT VENTRICULAR FUNCTION AT REST AND DURING DOBUTAMINE STRESS WITH SONOVUE®-ENHANCED REALTIME 3D-ECHOCARDIOGRAPHY

lead_sponsor: Bracco ALTANA Pharma GmbH


title:
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

 Étude de phase IIb/III, randomisée, en double aveugle, contrôlée contre placebo, à 2 bras, visant à évaluer l’efficacité et l’innocuité de la nalbuphine en comprimés à libération prolongée dans le prurigo nodulaire pour le soulagement du prurit par modulation des lésions de grattage (étude PRISM - Pruritus Relief through Itch Scratch Modulation)

lead_sponsor: Trevi Therapeutics, Inc.


title: A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy

lead_sponsor: GlaxoSmithKline Research & Development Limited


title:
A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE).
 And Pharmacogenetics Blood Sample Amendment Number 1 - Site Specific (Version 2.0, Date 19-Jan-07).


title: PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES

lead_sponsor: Pfizer Inc 235 East 42nd Street New York, NY 10017


title: Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer

lead_sponsor: Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA


title: A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: Randomized parallel-group, multicentre study to evaluate the after-use sensation and safety of carteolol LA 2% versus timolol LA 0.5% in simple intra-ocular hypertension and glaucoma.

lead_sponsor: Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH


title: A randomised, double-blind, double-dummy, active-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 90.9 181.8 and 363.6 μg b.i.d. administered via Respimat® inhaler and fluticasone propionate HFA MDI 440 μg b.i.d. in patients with asthma inadequately controlled on medium dose ICS therapy

lead_sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG


title:
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

 Essai de phase II, en ouvert, de pazopanib en monothérapie chez des patients porteurs de tumeurs fibreuses solitaires (SFT) et chondrosarcomes myxoïdes extra squelettiques (EMC), non résécables ou métastatiques.

acronym:
GEIS-32

 GEIS-32

lead_sponsor: Grupo Español de Investigación en Sarcomas


title: A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial hypertension

acronym: FUTURE 6

lead_sponsor: Actelion pharmaceuticals Ltd


title: A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid Tumors

lead_sponsor: Centocor B.V.


title: A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence

lead_sponsor: Laboratoires Merck Sharp & Dhome-Chibret


title: Effects of three oral dosages of S 44121 on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1. A 3-day, single-blind, international multicentre study.

lead_sponsor: Institut de Recherches Internationales Servier


title:
A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH
 ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLATIN-BASED THERAPY

lead_sponsor: Genentech, Inc


title: Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis

acronym: Long-term safety&tolerability of GSK2330672 as a treatment for cholestatic pruritus participants PBC

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion via a Pump System plus Additional Oral Administered Levodopa/Carbidopa versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension

lead_sponsor: NeuroDerm Ltd.


title: A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis®) in Patients with Localized Myxoid / Round Cell Liposarcoma

lead_sponsor: Pharma Mar, S.A.


title:
A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current Management

 Étude de phase 3b, en ouvert, à un seul bras, multicentrique visant à évaluer l’innocuité et l’efficacité du traitement par Pegvaliase (BMN 165) chez des adultes atteints de phénylcétonurie non contrôlée par la prise en charge actuelle

acronym: OPTIC Study

lead_sponsor: BioMarin Pharmaceutical Inc.

status: Not Authorised


title: A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta®) as Second Line Therapy in Patients with Advanced or Metastatic Non Small Cell Lung Cancer

lead_sponsor: Eli Lilly and Company limited


title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension

lead_sponsor: Conatus Pharmaceuticals Inc.


title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia

lead_sponsor: Genzyme Europe BV


title:
A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART.

 Essai randomisé évaluant une thérapie antirétrovirale basée sur le dolutegravir (DTG) en comparaison avec une thérapie antirétrovirale standard chez les enfants infectés par le VIH-1 commençant une première ligne ou  changeant pour une seconde ligne de traitement.

acronym: ODYSSEY (Once daily DTG-based ART in young people vs standard therapy)

lead_sponsor: Fondazione PENTA ONLUS


title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN CISPLATIN-INELIGIBLE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY (MORPHEUS-mUC)

lead_sponsor: F. Hoffmann-La Roche Ltd


title: Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects

lead_sponsor: Sanofi Pasteur SA


title: A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis

lead_sponsor: Novartis Pharma Services AG


title: An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.

lead_sponsor: Neurochem Inc


title: A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic infection.

lead_sponsor: Inserm-ANRS


title: A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired renal function

lead_sponsor: NV Organon


title:
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

 ÉTUDE DE PHASE 3, MULTICENTRIQUE, RANDOMISÉE, EN DOUBLE
 AVEUGLE ET CONTRÔLÉE PAR PLACEBO ÉVALUANT L'INNOCUITÉ ET
 L'EFFICACITÉ DU PF-06939926 DANS LE TRAITEMENT DE LA DYSTROPHIE
 MUSCULAIRE DE DUCHENNE

lead_sponsor: Pfizer Inc.


title: AN EXPLORATIVE PHASE IIa STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF VAS203 IN PATIENTS WITH MODERATE AND SEVERE TRAUMATIC BRAIN INJURY

lead_sponsor: vasopharm GmbH


title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation

lead_sponsor: BREATH Therapeutics Inc.


title: A Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)- positive oropharyngeal cancer

acronym: Post-operative adjuvant treatment for HPV-positive tumours (PATHOS)

lead_sponsor: Cardiff University


title: A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 45.5, 90.9 and 181.8 μg b.i.d. administered via Respimat® inhaler and fluticasone propionate HFA MDI 220 μg b.i.d. in patients with asthma inadequately controlled on low dose ICS therapy.

lead_sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG,


title: Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia

lead_sponsor: Octapharma AG


title: Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia

lead_sponsor: Institut de Recherches Internationales Servier


title: A Phase 2 Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

acronym: A phase II study of pembrolizumab in subjects with relapsed or refractory PMBCL

lead_sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck  Co., Inc


title:
OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL)

 Traitement par ocytocine chez les nouveau-nés et les nourrissons âgés de 0 à 3 mois présentant un syndrome de Prader-Willi : étude de la tolérance et de l’efficacité sur les troubles de l’oralité, les interactions sociales et le comportement alimentaire d’administrations intra-nasales d’ocytocine versus placebo (Étude clinique de phase III)

acronym:
OTBB3

 OTBB3

lead_sponsor: University Hospital of Toulouse


title: A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in patients with Multifocal Motor Neuropathy

lead_sponsor: LFB BIOTECHNOLOGIES


title:
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)

 Étude de recherche de dose randomisée, en double aveugle, contrôlée par placebo visant à évaluer la sécurité et l’efficacité du CCX140-B chez des sujets atteints de hyalinose segmentaire et focale (HSF)

lead_sponsor: ChemoCentryx, Inc.


title: A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates.

lead_sponsor: Amgen Inc


title:
A Phase 2, Open-Label, Single-Arm, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

 Étude de phase 2 multicentrique ouverte à un seul bras visant à évaluer l’AL101 chez des patients atteints de carcinome adénoïde kystique (CAK) présentant des mutations activant la voie Notch

acronym: ACCURACY Study

lead_sponsor: Ayala Pharmaceuticals, Inc.


title:
Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-related Behavior, Total Body Weight, and Safety Over 52 Weeks

 Essai de phase III randomisé, en double aveugle et contrôlé contre placebo, du béloranib chez les patients obèses présentant le syndrome de Prader-Willi, visant à évaluer le comportement alimentaire, le poids corporel total et l’innocuité pendant 52 semaines

acronym: bestPWS|EU

lead_sponsor: Zafgen Inc.


title: Rituximab as second line treatment for ITP: A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study. “The RITP study”

acronym: RITP study

lead_sponsor: Rikshospitalet


title: Effect of an octenidine-based topical antimicrobial agent (Octenisept) on wound healing of chronic venous leg ulcers: a prospective, twelve week comparison versus local treatment with Ringer solution. A randomised, double-blind, controlled, parallel-group, multicentre, multinational Phase IIIb study

lead_sponsor: Schülke & Mayr GmbH


title: A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection

lead_sponsor: F.Hoffmann-La Roche


title: A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a stable dose of a second generation antipsychotic.

acronym: Glycine uptake Inhibitor Add-on in Negative symptoms Trial (GIANT).

lead_sponsor: NV Organon


title: A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.

lead_sponsor: Gilead Sciences Inc


title: A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum

acronym: Comparison of once daily versus twice daily administration of PTK787/ZK 222584 in mCRC

lead_sponsor: Schering AG


title: A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects who Have  Chronic HCV-1/HIV-1 Co-Infection and are Treatment-Naïve for Hepatitis C

lead_sponsor: Vertex Pharmaceuticals Incorporated


title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer

lead_sponsor: Eli Lilly and Company limited


title: A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapy

lead_sponsor: Novartis Pharma Services AG


title: A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV)

lead_sponsor: Alnylam Pharmaceuticals, Inc.


title: An open-label, non-controlled multicentre trial to evaluate the insertion characteristics of the radiopaque etonogestrel implant using a next generation applicator


title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab versus Placebo in Males with Low Bone Mineral Density


title: Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy

lead_sponsor: PIERRE FABRE MEDICAMENT


title: A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus on Metformin

acronym: GBCF

lead_sponsor: Eli Lilly and Company - Indianapolis


title: SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of Locteron™ Plus Ribavirin Given Bi-weekly In Comparison With PEG-Intron™ Plus Ribavirin Given Weekly

lead_sponsor: Biolex Therapeutics Inc.


title: Exploratory study of the safety, tolerability and efficacy of nangibotide in mechanically ventilated patients with COVID-19 and features of systemic inflammation - A randomized, double-blind, placebo-controlled study with adaptive features.

lead_sponsor: INOTREM S.A.


title: Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders :  randomised, placebo-controlled, dose effect, double blind, parallel group study

lead_sponsor: PIERRE FABRE MEDICAMENT-IRPF-IDPF


title: Two Approaches to Escalate Lispro Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone

acronym: AUTONOMY

lead_sponsor: Eli Lilly and Company


title: An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

lead_sponsor: Global Blood Therapeutics, Inc.


title:
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR)

 Essai randomisé de phase II comparant l'Imatinib versus Imatinib + hydroxychloroquine chez les patients atteints d’une leucémie myéloïde chronique en phase chronique, en réponse cytogénétique majeure, mais avec une maladie résiduelle détectable par PCR (polymerase chain reaction)

acronym: CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cells

lead_sponsor: NHS Greater Glasgow and Clyde


title: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome

acronym: CARDINAL

lead_sponsor: Reata Pharmaceuticals, Inc.


title:
A Non-Interventional Study to Monitor the Survival Status of
 Patients that Discontinued from ISIS 420915-CS2 or
 ISIS 420915-CS3

 Étude non interventionnelle visant à surveiller le statut de survie des patients ayant quitté l'étude ISIS 420915-CS2 ou ISIS 420915-CS3

lead_sponsor: Ionis Pharmaceuticals, Inc.


title:
A RANDOMIZED, DOUBLE-BLIND, MULTICENTER,
 PLACEBO-CONTROLLED PHASE 3 STUDY WITH
 OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY
 AND SAFETY OF INEBILIZUMAB IN ADULTS WITH
 MYASTHENIA GRAVIS

acronym: Myasthenia Gravis INebilizumab Trial (MINT)

lead_sponsor: Viela Bio, Inc.


title: A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hyperoxaluria Type 3

lead_sponsor: Dicerna Pharmaceuticals, Inc.


title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) versus placebo in women with Mixed Urinary Incontinence

lead_sponsor: IXALTIS


title:
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

 Etude sur la désensibilisation de l’allergie à l’arachide par immunothérapie orale précoce (POSEIDON)

acronym: POSEIDON

lead_sponsor: Aimmune Therapeutics , Inc.


title:
A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

 Etude de Phase I/IIa évaluant TG6002 (VV TK-RR-FCU1) administré par perfusion intra-veineuse (IV) en association avec la flucytosine (5-FC) par voie orale chez des patients atteints de tumeurs gastro-intestinales (GI) avancées

lead_sponsor: TRANSGENE S.A.


title: Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis

lead_sponsor: Novo Nordisk A/S


title: Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)

acronym: ALPINE 4

lead_sponsor: NGM Biopharmaceuticals, Inc.


title: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors

acronym: MK-8628 Solid Tumor Trial

lead_sponsor: Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.


title: A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)

lead_sponsor: F.Hoffmann-La Roche Ltd


title: Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes

acronym: Safety and Efficacy of Moxidex Otic Solution in AOMT

lead_sponsor: Alcon Research Ltd.


title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6)

lead_sponsor: EORTC


title: ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients

acronym: ASPIRO

lead_sponsor: Audentes Therapeutics Inc.

status: Temporarily Halted


title: A Phase IIa randomised, double-blind, placebo controlled, parallel group,  multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)

lead_sponsor: AstraZeneca AB


title: A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma

lead_sponsor: GlaxoSmithKline Research & Development Limited


title: A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and young adults with acute myeloid leukemia in molecular relapse after first complete remission.

lead_sponsor: Celgene Corporation


title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic mutations

lead_sponsor: Rhythm Pharmaceuticals, Inc.


title: A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients with mild-moderate Alzheimer's Disease. ETHERAL Study

acronym: ETHERAL

lead_sponsor: Oryzon Genomics S.A.


title:
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab.

 Étude de phase II en ouvert, en un seul bras, du melflufen en association avec la dexaméthasone chez des patients présentant un myélome multiple en rechute/réfractaire qui ne répondent pas au pomalidomide et/ou au daratumumab

lead_sponsor: Oncopeptides AB


title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic

lead_sponsor: Rigel Pharmaceuticals, Inc.


title: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

lead_sponsor: Sellas Life Sciences


title:
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of   Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)

 Étude multicentrique de phase 2b, ouverte, à un seul groupe, évaluant l’efficacité et la tolérance de l’adavosertib en traitement du carcinome séreux de l’utérus récidivant ou persistant (ADAGIO)

acronym: ADAGIO


title: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma

lead_sponsor: GlaxoSmithKline Research and Development Ltd


title: A Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcriptase inhibitors, in HIV-1 infected antiretroviral treatment-naive adults

acronym: A Phase 2b Dose-Range Finding Clinical Trial in HIV-1 Infected Treatment-Naive Adults

lead_sponsor: ViiV Healthcare UK Limited


title: Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS)


title: A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in subjects with Alcoholic Hepatitis

lead_sponsor: DURECT Corporation


title: A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection

lead_sponsor: NovImmune S.A.


title: A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment

acronym: CodeBreaK 201

lead_sponsor: Amgen Inc.


title: A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia or Intermediate-2 or High-Risk Myelodysplastic Syndrome

lead_sponsor: Pharmion Corporation


title:
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

 Etude d’extension (roll-over) multicentrique, en ouvert, évaluant la tolérance à long terme de l’asciminib chez des patients ayant terminé une étude évaluant l’asciminib promue par Novartis et qui pourraient tirer un bénéfice de la poursuite du traitement selon l’avis du médecin-investigateur

lead_sponsor: Novartis Pharma AG


title: An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection

lead_sponsor: GlaxoSmithKline Research & Development Ltd


title: A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate the Pharmacokinetics and Safety of Solriamfetol in Pediatric Subjects  with Narcolepsy

lead_sponsor: Jazz Pharmaceuticals, Inc.


title:
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer
 (Master Protocol Revised version 02 dated 27-Jul-2016 + Sub-protocol 01 Revised version 01 dated 08-Apr-2016)

acronym: FRACTION-Lung

lead_sponsor: Bristol-Myers Squibb International Corporation


title:
An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies

 Étude d’innocuité, multicentrique, ouverte comparant, à dose fixe, l’association durvalumab-trémélimumab à la monothérapie par durvalumab dans les tumeurs solides à stade avancé (Etude STRONG)

acronym: STRONG

lead_sponsor: AstraZeneca AB


title: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment with Niraparib versus Ganetespib plus Carboplatin followed by Ganetespib and Niraparib versus Carboplatin in combination with standard chemotherapy followed by Niraparib maintenance treatment in platinum-sensitive ovarian cancer patients

acronym: EUDARIO: European Trial on enhanced DNA Repair Inhibition in Ovarian Cancer

lead_sponsor: Katholieke Universiteit Leuven


title: Phase 3 open-label study to evaluate efficacy, safety, and tolerability of FIX gene transfer with fidanacogene elaparvovec (PF-06838435) in pediatric male participants <18 years of age with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene 3)

lead_sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017


title: A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1 infected, treatment-naïve adults

acronym: DYNAMIC


title:
CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patients with severe Crigler-Najjar syndrome requiring phototherapy

 « CareCN : Etude de phase I/II,  en ouvert, avec escalade de dose, visant à évaluer la tolérance et l’efficacité d’un traitement par GNT0003 administré par voie intraveineuse chez des patients atteints d’un syndrome de Crigler-Najjar sévère nécessitant un traitement par photothérapie

acronym: CareCN

lead_sponsor: Genethon


title: A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD)


title: A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma.

lead_sponsor: Janssen-Cilag International N.V.


title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™)

acronym: CLEAREST™-TRAIL

lead_sponsor: Merck Serono International S.A.


title: GF-001001-00 cream.  A multicentre, randomised, double-blind, parallel, placebo-controlled phase II study to assess the efficacy and safety of 3 different doses of GF-001001-00 cream versus placebo cream applied 2 times daily for 7 days in the treatment of adult patients with secondarily-infected traumatic lesions.

lead_sponsor: Ferrer International, SA


title: A Non-inferiority Comparison of 35mg Delayed-release Risedronate, Administered Once-weekly Either Before or After Breakfast, and 5mg Immediate-release Risedronate, Administered Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis as Assessed Over 2 Years; a Phase III, Multicenter, Double-Blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study

acronym: Fantasia Phase III

lead_sponsor: Procter & Gamble Pharmaceuticals


title: A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults

acronym: Ph 2a, GSK3640254, POC in HIV-1 infected Treatment-naive Adults

lead_sponsor: ViiV Healthcare UK Limited


title: EFFICACY AND TOLERABILITY OF CHONDROITIN SULPHATE 1000MG, TWICE DAILY IN PATIENTS WITH SYMPTOMATIC KNEE OSTEOARTHRITIS

lead_sponsor: PIERRE FABRE MEDICAMENT


title:
A RANDOMISED, SINGLE-BLIND, ACTIVE CONTROLLED, MULTI-CENTRE TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, ACCEPTABILITY AND PALATABILITY OF PMF104 COMPARED TO A CONVENTIONAL PEG-ELECTROLYTE SOLUTION IN CHILDREN  AGED FROM 2 TO LESS THAN 6, FROM 6 TO LESS THAN 12 AND ADOLESCENTS FROM 12 TO LESS THAN 18 YEARS OF AGE REQUIRING A DIAGNOSTIC PROCEDURE CONCERNING THE COLON (EMA Decision P/019/2017 on the acceptance of modification of Paediatric Investigation Plan)

 Essai multicentrique, randomisé, en simple aveugle, contrôlé par substance active, visant à évaluer l’efficacité, la sécurité d’emploi, la tolérance, l’acceptabilité et la palatabilité du PMF104 par comparaison à une solution électrolytique conventionnelle contenant du PEG, chez des enfants âgés de 2 ans à moins de 6 ans, de 6 ans à moins de 12 ans et chez des adolescents âgés de 12 ans à moins de 18 ans, devant subir une procédure à visée diagnostique concernant le côlon  (Décision de l’EMA P/019/2017 relative à l’approbation de modification du Plan d’Investigation Pédiatrique)

lead_sponsor: Alfa Wassermann S.p.A.


title:
TEMOkids study (ORP-TMZ-I- b): A Population pharmacokinetic, acceptability and safety study for KIMOZO, a paediatric oral suspension of temozolomide

 Etude TEMOkids (ORP-TMZ-I- b): Etude de pharmacocinétique de population, d’acceptabilité et de sécurité d’emploi de Kimozo, suspension buvable pédiatrique de témozolomide

acronym:
TEMOkids study

 Etude TEMOkids

lead_sponsor: ORPHELIA Pharma


title: An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19

lead_sponsor: sanofi-aventis recherche & développement


title:
MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

 MOUNTAINEER : Étude de phase 2, en ouvert portant sur le tucatinib associé au trastuzumab chez des patients atteints de cancer colorectal métastatique HER2+

lead_sponsor: Seattle Genetics, Inc.


title: A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribavirin

lead_sponsor: Schering Plough Research Institute, A Division of Schering Corporation


title: LONG-TERM MANAGEMENT OF ATOPIC DERMATITIS WITH THE EMOLLIENT V0034 CR.  A RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUPS,  DOUBLE-BLIND STUDY IN INFANTS AND CHILDREN

acronym: Not applicable


title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Naïve HIV-Infected Patients, Each in Combination With TRUVADA™

lead_sponsor: Laboratoires Merck Sharp & Dohme-Chibret


title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Recipients of Autologous Hematopoietic Cell Tranplants (HCTs)

lead_sponsor: Laboratoires Merck Sharp & Dohme - Chibret


title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation

lead_sponsor: Theratechnologies Inc.


title: A Randomized, Double Blinded, Multi-Center Study 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney

lead_sponsor: Amgen Inc.


title: An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicine

lead_sponsor: Novartis Pharma Services AG


title: Evaluation de l’effet anesthésique du protoxyde d’azote dans une population d’opérés recevant une anesthésie totale intraveineuse en « boucle » guidée par l’index bispectral (Effect of nitrous oxide on intra-venous closed-loop anesthesia)

acronym: Drone-Proto

lead_sponsor: Hopital Foch


title: An Investigator-initiated study on rFVIIa prophylaxis in children with haemophilia A and inhibitors

acronym: ENJOIH 01

lead_sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico


title:
AN OPEN LABEL PHASE II STUDY  TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR-ABL+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).
 EWALL-PH-01

acronym: EWALL

lead_sponsor: CH-Versailles


title:
A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.

 Une étude de 12 semaines, en double aveugle, groupes paralèlles, 1:1, randomisée versus placebo de l'efficacité et la tolérance de la rispéridone chez les enfants et adolescents de 5,0 à 17,9 ans ayant un trouble des conduites selon les critères du DSM-IV.

acronym:
CONCA

 CONCA

lead_sponsor: Radboud University Medical Centre Nijmegen


title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations

lead_sponsor: Merck & Co. Inc.


title: An open-label, one arm, multi-centre Phase II trial evaluating the efficacy and safety of DTS-201 as a second-line chemotherapy in patients with hormone refractory prostate cancer

lead_sponsor: Diatos S.A.


title: A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with essential hypertension


title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot evaluation of therapeutic drug monitoring (TDM).  An open-label, multicenter, multinational trial with randomisation to standard of care (SOC) or TDM TPV/r therapy

lead_sponsor: Boehringer Ingelheim France SAS


title: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of CUV1647 for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients

acronym: Phase II AK Study

lead_sponsor: Clinuvel Pharmaceuticals Limited


title: VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER

lead_sponsor: STEBA BIOTECH SA


title: Safety of SCH 527123 in Subjects with Neutrophilic Asthma

lead_sponsor: Schering-Plough Research Institute, a Division of Schering Corporation


title: A multi-center, randomized, double-blind, controlled dose-finding study to evaluate the safety and efficacy of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock

lead_sponsor: Sangart, Inc.


title: International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression

lead_sponsor: ORVACS


title: An international multicentre, randomized, parallel group, double-blind trial to evaluate different dose combinations of lercanidipine and enalapril in comparison with each component administered alone and with placebo in patients with essential hypertension.

lead_sponsor: Recordati S.p.A.,


title:
Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study

 Efficacité et sécurité d’une double dose d’icodextrine chez des patients âgés, incidents en dialyse péritonéale continue ambulatoire (DPCA), débutant une dialyse péritonéale incrémentale: l’étude DIDo

acronym: DIDo

lead_sponsor: Université catholique de Louvain


title: A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and the pharmacokinetics of GSK221149A administered orally in healthy, pregnant females, with uncomplicated pre-term labor between 30 0/7 – 35 6/7 weeks gestation.

lead_sponsor: GlaxoSmithKline Research and Development


title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo- and Active Comparatorcontrolled
 Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

acronym: Delphinus

lead_sponsor: Otsuka Pharmaceutical Development & Commercialization,Inc


title: A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression

lead_sponsor: Dainippon Sumitomo Pharma America Inc.